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Dendritic cells (DCs) are key regulators of the immune system that shape T cell responses.
Regulation of T cell induction by DCs may occur via the intracellular enzyme indoleamine
2,3-dioxygenase 1 (IDO), which catalyzes conversion of the essential amino acid trypto-
phan into kynurenine. Here, we examined the role of IDO in human peripheral blood
plasmacytoid DCs (pDCs), and type 1 and type 2 conventional DCs (cDC1s and cDC2s).
Our data demonstrate that under homeostatic conditions, IDO is selectively expressed by
cDC1s. IFN-γ or TLR ligation further increases IDO expression in cDC1s and induces mod-
est expression of the enzyme in cDC2s, but not pDCs. IDO expressed by conventional DCs
is functionally active as measured by kynurenine production. Furthermore, IDO activity
in TLR-stimulated cDC1s and cDC2s inhibits T cell proliferation in settings were DC-T
cell cell-cell contact does not play a role. Selective inhibition of IDO1 with epacadostat, an
inhibitor currently tested in clinical trials, rescued T cell proliferation without affecting DC
maturation status or their ability to cross-present soluble antigen. Our findings provide
new insights into the functional specialization of human blood DC subsets and suggest a
possible synergistic enhancement of therapeutic efficacy by combining DC-based cancer
vaccines with IDO inhibition.
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Introduction
Dendritic cells (DCs) are professional antigen-presenting cells
that can both induce and regulate T cell priming. One of
the mechanisms by which DCs can negatively regulate T cell
responses is via the intracellular enzyme indoleamine 2,3-
dioxygenase 1 (IDO). IDO catalyzes breakdown of tryptophan
into N-formyl-kynurenine, the first and rate-limiting step in tryp-
tophan catabolism. Tryptophan deprivation, sensed by riboso-
mal kinase GCN2, and tryptophan metabolites such as kynure-
nine, inhibit effector T cell proliferation and induce anergy or
apoptosis [1–3]. In regulatory T cells (Tregs), however, GCN2
signaling leads to activation and induces a strong suppressive
phenotype [4]. Furthermore, both IDO-mediated GCN2 activa-
tion and binding of kynurenine to the aryl hydrocarbon recep-
tor promote de novo Treg differentiation from naïve CD4+
T cells [5,6].
IDO appears to play an important role in inducing tolerance
and limiting excessive inflammation, for instance in the placenta
[7]. In some settings, however, IDO activity might actually be
detrimental to the host. Cancer cells and myeloid-derived sup-
pressor cells often express IDO to inhibit antitumor immunity
and high IDO expression is associated with poor prognosis and
shorter overall survival in several cancer types, including ovar-
ian cancer [8], endometrial cancer [9], colorectal cancer [10],
and melanoma [11]. Primary DCs are currently under investiga-
tion for their use in cancer vaccines, which aim at boosting the
antitumor-specific T cell response. Because IDO activity inhibits T
cell function, expression of IDO by human DC subsets may have
important implications for the efficacy of DC-based immunother-
apy.
Multiple types of inflammatory signals may induce IDO
expression in DCs. IDO1 gene promoters contain several inter-
feron (IFN) response elements, allowing transcription of IDO
upon signaling by type I IFNs, and more effectively by type II
IFN (IFN-γ) [12,13]. Other inducers of IDO include ligation of
CD40 and Toll-like receptors (TLRs), and reverse signaling by B7
molecules upon ligation by CTLA-4 [14–17]. Importantly, IDO
expression at the protein level does not necessarily correlate with
biological activity of the enzyme. For instance, a combination
of different signals was shown to be required to achieve full
enzymatic activity in human monocyte-derived DCs (moDCs)
[14,18].
Most studies on IDO expression by DCs have been performed
with murine DCs and human moDCs. In contrast, less is known
about the function of IDO in human primary DCs, which are
subdivided into three major subsets: plasmacytoid DCs (pDCs)
and type 1 and type 2 conventional DCs (cDC1s and cDC2s).
Interestingly, RNA profiling revealed high IDO expression by
human steady-state and activated cDC1s [19–22]. Our recent
comparative proteomic analysis of steady-state human DC subsets
likewise revealed IDO protein to be uniquely expressed by cDC1s
[23]. Here, we compared the expression and activity of IDO
in immature and stimulated human peripheral blood DCs and
studied the effects on T cell proliferation.
Results
Immature cDC1s selectively express high levels of
functionally active IDO
High expression of IDO by human cDC1s compared to cDC2s
and pDCs was first reported on RNA level by Crozat et al.
[19], using a dataset generated with RNA microarray [24]. More
recently, single-cell RNA-sequencing (RNA-seq) analysis of steady-
state human blood DC subsets also demonstrated IDO to be
uniquely associated with cDC1s [20,21]. Furthermore, IDO1 gene
expression was higher in cDC1s compared to cDC2s and pDCs in
human tonsil [25], and thymus and spleen [26]. We confirm these
findings by combining a bulk RNA-seq dataset of blood cDC1s
(Mathan et al. manuscript in preparation) and a bulk RNA-seq
dataset of blood cDC2s and pDCs [27], both generated by our
group. Comparing the total prevalence of the genes that Villani
et al. found to be specific for cDC1s [20] revealed that IDO1 is,
together with XCR1 and CADM1, the most uniquely expressed
gene by cDC1s, compared to cDC2s and pDCs (Fig. 1A). Moreover,
IDO1 gene expression in cDC1s is increased upon stimulation with
TLR3 or TLR7/8 agonists (Fig. 1B).
Comparative proteomic analysis in steady-state human blood
DC subsets revealed that also at the protein level, IDO was highly
expressed by cDC1s, while the signal was below detection limit for
cDC2s and pDCs (Fig. 2A) [23]. Analysis of immature blood DCs
by flow cytometry confirmed significantly higher IDO expression
by cDC1s compared to cDC2s and pDCs (Fig. 2B).
We next analyzed IDO activity across DC subsets by measure-
ment of L-kynurenine levels in supernatants from 24-hour DC cul-
tures by high-performance liquid chromatography (HPLC). cDC1s
converted around 1 μM tryptophan into kynurenine, whereas
the same number of pDCs and cDC2s produced less kynure-
nine (Fig. 2C). Taken together, immature human peripheral blood
cDC1s express functionally active IDO at significantly higher lev-
els than cDC2s and pDCs.
IDO is induced in cDC2s and upregulated in cDC1s by
TLR ligation or IFN-γ stimulation
Upon activation, DCs acquire the capacity to migrate to the
draining lymph node and express co-stimulatory molecules
needed to activate T cells. Hence, DC-based vaccines using
mature DCs induce superior immunological responses compared
to vaccines using immature DCs [28]. We therefore extended
our analysis of IDO expression to TLR ligand-matured DCs
(Supporting Information Fig. 1). Furthermore, since IFN-γ is
a potent inducer of IDO and is highly produced by effector T
cells, IFN-γ stimulation is relevant in vivo and was therefore also
included in the analysis. DC subsets isolated from peripheral
blood were cultured overnight with the indicated stimuli and IDO
protein expression was analyzed by flow cytometry (Fig. 3A and
B), while IDO enzyme activity was determined by measurement
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Figure 1. IDO1 is among the genes that best defines peripheral blood cDC1s under homeostatic conditions and its expression is increased upon
stimulation with TLR agonists. Gene expression was analyzed from RNA-seq datasets. Z scores were calculated using normalized and log trans-
formed counts per million values. Means are depicted. (A) Expression of selected genes was compared between immature cDC1s, immature cDC2s,
and immature (unstimulated or IL-3-treated) pDCs, of 4 (cDC1) or 3 (cDC2 and pDC) different donors. (B) IDO1 gene expression among cDC1s of three
or four different donors cultured overnight in absence or presence of a clinical grade TLR3 agonist (Hiltonol) and/or TLR7/8 agonist (protamine-RNA).
of kynurenine production in supernatants by HPLC (Fig. 3C).
Importantly, while immature cDC2s showed only minimal levels
of IDO expression and activity, stimulation with IFN-γ or the
combination of TLR3-agonist polyinosinic:polycytidylic acid
(poly(I:C)) with TLR7/8 agonist resiquimod (R848) increased
both protein expression and enzyme activity in this DC subset.
cDC1s stimulated with IFN-γ or the combination of poly(I:C) and
R848 maintained and further increased IDO protein expression
and activity, to levels higher than found in cDC2s (Supporting
Information Fig. 2). High kynurenine production by IFN-γ-
stimulated cDC1s was reduced upon addition of the IDO1-specific
inhibitor epacadostat (Supporting Information Fig. 3), indicating
that kynurenine production is IDO-dependent. In contrast, pDCs
stimulated with IFN-γ, R848 or TLR9-agonist CpG oligodeoxynu-
cleotide class C (CpG-C) did not upregulate IDO expression or
activity (Fig. 3B and C). Thus, TLR ligation or IFN-γ stimulation
induces IDO expression and activity in cDC1s and cDC2s, but not
pDCs.
© 2021 The Authors. European Journal of Immunology published by
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Figure 2. Immature cDC1s, but not cDC2s and pDCs, express functionally active IDO. (A) IDO1 protein expression among steady-state human blood
DCs of three different donors was analyzed from a proteomics dataset. Means are depicted. (B) IDO intracellular protein expression was analyzed
by flow cytometry in DCs cultured overnight. The graph shows the geometric mean fluorescent intensity (MFI) of IDO expression subtracted by the
MFI of the isotype control, with at least seven different donors per condition from 10 independent experiments. Means are depicted. Significance
was determined by one-way ANOVA with Bonferroni correction (***P < 0.001). (C) IDO activity was analyzed by measuring l-kynurenine in super-
natants of 24-h DC cultures by HPLC. Results are from six different donors from four independent experiments; in one experiment (squares), pooled
supernatants from 3 different donors were used. Means are depicted and symbols correspond to measurements belonging to the same donors.
Significance was determined by repeated measures one-way ANOVA with Bonferroni correction (*P < 0.05).
Epacadostat-treatment of cDC1s and cDC2s prevents
IDO-mediated inhibition of T cell proliferation
Human blood DC subsets express high levels of stimulatory
molecules upon maturation and are known for their T cell stim-
ulatory capacity [29]. However, IDO activity can inhibit T cell
responses by depleting tryptophan and by increasing toxic kynure-
nine metabolites. To test whether IDO expressed by human blood
DC subsets affects T cell proliferation, peripheral blood lympho-
cytes (PBLs) were stimulated with anti-CD3/anti-CD28 antibody-
coated beads in DC-conditioned medium. T cell proliferation
was inhibited by supernatant of cDC1s or cDC2s matured with
poly(I:C) and R848 or stimulated with IFN-γ (Fig. 4A); this inhibi-
tion could be partially rescued by specifically blocking IDO activity
with epacadostat, with statistically significant differences for the
conditions where cDCs were stimulated with TLR ligands. In con-
trast, treating pDCs with epacadostat did not affect T cell prolif-
eration. These findings are in accordance with the IDO expression
and activity data and underline the functional relevance of IDO
activity by human cDCs on T cell proliferation.
The effect of IDO on DC-induced T cell proliferation was fur-
ther studied in a mixed lymphocyte reaction (MLR). All three
primary DC subsets induced allogenic T cell proliferation, but
inhibition of IDO did not substantially affect T cell prolifera-
tion (Fig. 4B), in contrast to the assay with DC-conditioned
medium. Yet, addition of epacadostat to moDCs stimulated with
LPS and IFN-γ to express high levels of IDO [30] was able to
increase allogeneic T cell proliferation (Supporting Information
Fig. 4). This suggests that IDO activity in primary cDCs has
only limited inhibitory effects in settings were these cells have
contact-mediated interactions with T cells. While poly(I:C) and
R848 stimulation induces IDO activity (Fig. 3), this potent com-
bination of TLR agonists is also known to strongly upregulate
costimulatory molecules and cytokine production [29]. These
findings might therefore reflect the complex interplay of
inhibitory and stimulatory molecules expressed or secreted by DCs
in T cell priming.
Epacadostat is currently under investigation in several clini-
cal trials. Although its effects as a single treatment appear lim-
ited, several clinical studies suggest that IDO inhibition might
potentiate the effects of other cancer immunotherapies [31]. To
achieve a successful combination of epacadostat with DC-based
immunotherapy, the inhibitor should not negatively affect DC
function. Cross-presentation of exogenous antigens on MHC class
I enables DCs to prime CD8+ T cells, which is crucial for induction
of anti-tumor immunity. In humans, all blood DC subsets are capa-
ble of cross-presenting soluble antigens [32], although cDC1s are
superior at cross-presenting cellular antigens [33–36]. We there-
fore tested the effect of epacadostat on the capacity of cDC1s,
cDC2s and pDCs of HLA-A2.1+ donors to cross-present soluble
gp100(272-300) peptide to T cells transduced with a T cell recep-
tor specific for the gp100(280-288) peptide. Cross-presentation of
gp100(272-300) peptide requires intracellular processing in order
to release the HLA-A2.1-restricted gp100(280-288) epitope. In line
with our expectations, all DC subsets effectively cross-presented
soluble gp100(272-300) (Fig. 5). IDO inhibition by epacadostat did
not significantly change the ability of any of the three primary
DC subsets, nor moDCs (Supporting Information Fig. 5), to cross-
present soluble antigen.
The IDO inhibitor 1-methyl-tryptophan has been reported to
partially inhibit the maturation of moDCs in response to cer-
tain TLR agonists [15]. We, therefore, tested whether epaca-
dostat treatment affects the expression of membrane molecules
on DC subsets that are normally upregulated upon maturation,
as well as the production of IL-12 by cDC subsets. Epacadostat
treatment did not substantially change the expression of MHC-I
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Figure 3. IDO protein expression and activity among stimulated blood DC subsets. (A) Flow cytometry histograms from a representative donor
showing isotype control (solid grey line), IDO expression in absence of stimulus (dashed black line), and IDO expression for either IFN-γ or CpG-C
stimulation (solid black line) for cDCs or pDCs, respectively. (B) The figure shows the geometric mean fluorescence intensity (MFI) of IDO expression
subtracted by the MFI of the isotype control, with at least 3 different donors per condition from 10 independent experiments. Bars representmeans.
Significancewas determined by one-way ANOVAwith Bonferroni correction, comparing stimulated DCswith immature control (*P< 0.05; **P< 0.01).
(C) IDO activity was analyzed by measuring l-kynurenine in supernatants of 24-h DC cultures by HPLC. The results are from six different donors
from four independent experiments; in one experiment (squares), pooled supernatants from 3 different donors were used. Bars represent means
and symbols correspond to measurements belonging to the same donors. Significance was determined by repeated measures one-way ANOVA
with Bonferroni correction, comparing stimulated DCs with their immature control (*P < 0.05).
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Figure 4. IDO expressed by cDCs inhibits T cell proliferation. Blood DCs were stimulated with indicated stimuli and/or epacadostat in medium
containing 10 μM tryptophan. (A) PBLs were stimulated with anti-CD3/CD28-coated beads in supernatants of 48-hour DC cultures and proliferation
was measured after three days by tritiated thymidine incorporation. Mean proliferation in counts per minute (cpm) of three different donors from
3 independent experiments with technical triplicates (cDC2, pDC) or duplicates (cDC1) is shown. Symbols correspond to measurements belonging
to the same donors. Significance was determined by two-tailed paired t-test comparing absence vs presence of IDO inhibitor (*P < 0.05; **P < 0.01).
(B) Allogeneic PBLs were cultured with overnight-stimulated DCs and proliferation was measured after another three days by tritiated thymidine
incorporation. Mean proliferation of at least three different donors from four independent experiments with technical triplicates (cDC2, pDC) or
duplicates (cDC1) are shown. Symbols correspond to measurements belonging to the same donors. Significance was determined by two-tailed
paired t-test, comparing absence versus presence of IDO inhibitor.
(HLA-ABC), MHC-II (HLA-DR), CD40, CD80, CD83, CD86, CCR7,
PD-L1, or IL-12 by any of the three DC subsets upon matu-
ration by TLR3 and/or TLR7/8 agonists (Supporting Informa-
tion Fig. 6A and B). Taken together, epacadostat enhances T
cell proliferation induced by TCR cross-linking in the presence
of supernatant of TLR-stimulated cDCs, while it does not inter-
fere with DC maturation or their ability to cross-present solu-
ble antigen. These properties make this IDO inhibitor an inter-
esting candidate to enhance the efficacy of DC-based cancer
immunotherapies.
Discussion
DCs can limit T cell responses via IDO activity. Although IDO is
well-characterized in murine DCs and human moDCs, much less
is known about its activity and function in human primary DCs.
Here, we compared the expression and activity of IDO across the
three major human DC subsets found in peripheral blood. We
describe a functional role for IDO in cDCs, in particular in cDC1s.
RNA expression profiling of steady-state human DC subsets
showed unique IDO1 expression by cDC1s [19–21]. We confirm
that among immature DCs, IDO1 is one of the most uniquely
expressed genes by cDC1s. Using flow cytometry, we demonstrate
that IDO is also uniquely expressed at the protein level by imma-
ture cDC1s, which corroborates our previous study using pro-
teomics [23]. We expand on this data by showing that IDO in
immature cDC1s is biologically active, as it leads to the conver-
sion of tryptophan into kynurenine. Upon stimulation with IFN-γ
or TLR agonists, its expression and activity is further increased
and can limit T cell proliferation. Of note, human cDC1s have
also been reported to specifically express the IDO1-paralog gene
IDO2 [19,22], but its expression at the protein level, activity, and
functional role have not been investigated here.
Human cDC1s are considered the equivalent of murine CD8α+
DCs [19,33,34,36–38]. Likewise, murine CD8α+ DCs can mediate
© 2021 The Authors. European Journal of Immunology published by
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Figure 5. IDO inhibition by epacadostat does not affect the ability of DCs to cross-present soluble antigen to T cells. Blood DCs were stimulated
overnight with R848 (pDCs) or R848 and poly(I:C) (cDCs) in medium containing 1 μM tryptophan, with or without epacadostat, and loaded with
gp100(154-162) (irrelevant), gp100(280-288) (short), or gp100(272-300) (long) peptide.After overnight culture,T cells expressing the T cell receptor recognizing
gp100(280-288) were added at a 1:5 DC:T cell ratio for 24 h. CD69 expression by T cells was used as a readout for DC-induced T cell stimulation and
was measured by flow cytometry. Mean frequency of CD69high cells among live CD3+ T cells is shown, with at least seven different donors per
condition from 11 independent experiments, with technical duplicates for cDC2 and pDC conditions. Significance was determined by two-tailed
paired t-test, comparing absence versus presence of IDO inhibitor (ns, non-significant).
T cell suppression via IDO [39]. Interestingly, CD8α+ DCs con-
stitutively express IDO, but the enzyme requires additional sig-
naling through IFN-γ or CTLA-4 to become biologically active
[40,41]. We show that although signaling via IFN-γ increases
IDO expression and activity in human cDC1s, it is not needed
per se for its enzymatic activity. Human cDC1s, like their murine
counterpart, are excellent cross-presenters and primers of T cells
[37]. Expression of immunosuppressive IDO by this potent pro-
inflammatory immune cell seems paradoxical. Yet, cDC1s express
the C-type lectin receptor CLEC9A to efficiently induce immune
responses towards dead cell antigens [33]. It is crucial that during
homeostasis, apoptotic self-antigens do not provoke an immune
response, for this may lead to systemic autoimmunity. IDO has
been reported to regulate tolerance to apoptotic antigens in mice
[42]. Hence, preferential expression of IDO in cDC1s could func-
tion as a safeguard mechanism, ensuring default immunosup-
pressive function in absence of pathogen- or danger-associated
molecular patterns. In addition, upregulation of IDO by stimu-
lated cDC1s might serve as a negative feedback mechanism to
prevent excessive T cell stimulation. These hypotheses should be
tested in future studies.
cDC2s do not express IDO when immature, but upregulate it
upon exposure to TLR3 and TLR7/8 agonist or IFN-γ. Production
of kynurenine by human cDC2s has also been reported in response
to LPS, E. coli, or prostaglandin E2 [43,44]. In our assays, the
supernatant from TLR-stimulated cDC1s as well as cDC2s had a
functional impact on T cell proliferation induced by TCR crosslink-
ing. Inhibition of T cell proliferation was dependent on IDO and
independent of cell-cell contact, probably by depleting tryptophan
and/or enriching T cell inhibitory breakdown products of trypto-
phan. Stimulatory cell-cell contact between cDCs and T cells in
an MLR seems to overpower IDO-mediated inhibition, as block-
ing IDO did not boost T cell proliferation in this setting. Still, IDO
activity in cDCs might become functionally relevant in the tumor
microenvironment, where the enzyme’s activity can contribute to
other immunosuppressive signals.
Our data show that immature human pDCs exhibit no or very
low IDO expression, which is in accordance with a study by Tra-
banelli et al. [44], as well as RNA expression profiling of steady-
state human DC subsets [19]. We also found very low expression
and activity of IDO in pDCs stimulated with CpG-C, R848, or IFN-
γ. Nevertheless, this does not rule out the possibility that human
pDCs are able to express functional IDO in other settings. Indeed,
IDO expression by human pDCs has been reported upon stimula-
tion by HIV, CpG-A or CpG-B [45,46]. Gerlini et al. identified IDO-
expressing pDCs in metastatic sentinel lymph nodes of melanoma
patients [47]. pDCs from control lymph nodes and the blood of
these patients did not express IDO, suggesting that expression of
the enzyme by human pDCs can be induced by tumors.
By using the IDO1-selective inhibitor epacadostat, we were
able to increase T cell proliferation in conditioned medium of
cDC1s or cDC2s. Epacadostat was demonstrated to be safe in
phase I/II clinical trials, and is currently being tested in multiple
phase III trials in combination with checkpoint blockade [31,48].
Our results suggest that epacadostat could alternatively be used in
combination with DC-based cancer immunotherapies to increase
inflammatory responses. Besides combining systemic epacadostat
treatment with DC-based cancer therapies, epacadostat might also
© 2021 The Authors. European Journal of Immunology published by
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be used during DC vaccine preparation. Treating conventional
DCs ex vivo with epacadostat prior to injection into the patient
could potentially enhance efficacy of immunostimulatory DC vac-
cines.
Materials and methods
RNA sequencing and proteomic analysis
RNA-seq analysis was performed on a dataset of cDC2s and
pDCs deposited at the Gene Expression Omnibus (accession
number: GSE89442) [27] and a dataset of cDC1s (Mathan et al.
manuscript in preparation). Data were analyzed using the R plat-
form for statistical computing. Count values from both datasets
were normalized and log-transformed, before calculating Z scores
using the edgeR package [49]. Proteomics analysis was performed
on a dataset of cDC1s, cDC2s and pDCs deposited at the Pro-
teomeXchange Consortium (dataset identifier: PXD004678) [23].
Cell isolation and culture
Human primary DCs were isolated from buffy coats or apheresis
products (Sanquin, Amsterdam, The Netherlands) obtained from
healthy volunteers after written informed consent and according
to institutional guidelines. Peripheral blood mononuclear cells
were obtained via ficoll density gradient centrifugation. DCs were
isolated by FACS sorting after enrichment with Dynabeads Human
DC enrichment kit (Invitrogen, Carlsbad, CA). The remaining
cells were incubated with anti-Lin1-FITC, anti-HLA-DR-PE-Cy7
(both BD Biosciences, Franklin Lakes, NJ), anti-CD1c-BV421
(Biolegend, San Diego, CA), anti-CD141-APC and anti-CD304-PE
(both Miltenyi Biotec, Bergisch Gladbach, Germany). The cells
were sorted on a BD Aria II from lineage negative, HLA-DRhigh
cells into three different populations, based on the expression
of CD141, CD1c or CD304 to obtain cDC1s, cDC2s, or pDCs,
respectively. In some experiments as indicated, DC subsets were
isolated from PBLs with magnetic microbeads by MACS sorting
(Miltenyi Biotec). PBLs were prepared by depleting monocytes via
anti-CD14-conjugated microbeads or adherence to plastic culture
flasks. To generate immature moDCs, monocytes were cultured
in X-VIVO 15 medium supplemented with 2% human serum,
300 IU/mL IL-4 and 450 IU/mL GM-CSF (both ImmunoTools,
Friesoythe, Germany) for 7 days. For mature moDCs, a maturation
cocktail was added for the last day of the culture period.
Cells were cultured in either X-VIVO 15 medium (Lonza,
Basel, Switzerland) supplemented with 2% human serum
(Sigma–Aldrich, Saint Louis, MO), hereinafter described as
complete X-VIVO medium, or in custom-made tryptophan-free
RPMI 1640 (Gibco/Thermo Fisher Scientific, Waltham, MA)
supplemented with 2 mM ultraglutamine (Lonza), 1% antibiotic-
antimycotic (Gibco), 10% human serum albumin (Sanquin) and
the indicated concentration of L-tryptophan (Merck, Darmstadt,
Germany), hereinafter described as complete RPMI medium.
DCs were incubated with stimuli as indicated: 4 μg/mL R848,
20 μg/mL poly(I:C), 5 μg/mL CpG-C (all Enzo Life Sciences,
Farmingdale, NY), 100 ng/mL LPS (Sigma–Aldrich), or 10 ng/mL
IFN-γ (Thermo Scientific). In the absence of activation stimulus,
10 ng/mL recombinant human IL-3 (CellGenix) was added to
pDC cultures as survival factor.
Flow cytometry
Flow cytometry experiments were performed according to the
guidelines by Cossarizza et al. [50]. To analyze IDO expression,
DCs were isolated by MACS sorting and cultured for 16 h in com-
plete X-VIVO medium with indicated stimuli. The next day, cells
were stained extracellularly with anti-CD141-PE for cDC1s, anti-
CD1c-PE for cDC2s, or anti-CD304-PE (all Miltenyi Biotec) for
pDCs. Cells were subsequently fixed, permeabilized, and stained
intracellularly with anti-IDO-A488 (clone #700838; R&D sys-
tems, Minneapolis, MN). Cells were measured on a BD FACS Cal-
ibur and data were analyzed by FlowJo software (see Supporting
Information Fig. 7 for the gating strategy).
To analyze maturation marker expression upon treatment with
epacadostat, DCs were isolated by FACS sorting and cultured at
1 × 104 DCs/well for 16 hours in complete RPMI medium with
1 or 10 μM L-tryptophan, indicated stimuli and with or with-
out 10 μM epacadostat (INCB024360; Selleck Chemicals, Hous-
ton, TX). After overnight culture, cells were labeled with fixable
viability dye eFluor-780 (eBioscience), anti-CD80-FITC (Biole-
gend), anti-CD83-APC, anti-CD86-PE-Cy7, anti-HLA-ABC-V450,
anti-HLA-DR-BV510 (all BD Biosciences), anti-PD-L1-APC (Biole-
gend), CD40-PE (Immunotech/Beckman Coulter, Brea, CA), and
anti-CD1b/c-FITC (Diaclone, Besancon Cedex, France) or anti-
CD303-FITC (Miltenyi Biotec). Expression of maturation markers
on live DCs was determined on a BD FACSVerse and data were
analyzed by FlowJo software.
Cytokine detection
Supernatants of DCs cultured at 1 × 104 DCs/200μL/well with
indicated stimuli were analyzed with standard sandwich ELISAs
detecting IL-12p70 (Biolegend).
Kynurenine quantification
DCs were isolated by FACS sorting and 80 × 103 DCs were
cultured at 0.5 × 106 cells/mL for 24 h in complete X-VIVO
medium and indicated stimuli. Conditioned media were ana-
lyzed for L-kynurenine by HPLC. Samples were pretreated with
perchloric acid to precipitate proteins. Samples were pretreated
(5:1) with 20% formic acid. 200 μL of samples was mixed with
200 μL buffer (0.77 g/L NH4Ac, 100 mg/L EDTA-Na2, 375 mg/L
NaCl, 37.5 mL/L MeOH; pH 5.35). Pure kynurenine (Sigma-
Aldrich) was used for calibration. Samples were injected into an
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Acquity Ultra Performance Liquid Chromatography (UPLC) sys-
tem (Waters, Milford, MA), consisting of an autosampler, injector,
column (Acquity UPLC HSS T3 1.8 μm; 2.1 × 100 mm) and UV
detector (Waters) at 360 nm. Chromatographic separation was
performed at an elution rate of 0.3 mL/min buffer.
T cell proliferation assays
For the proliferation assay with conditioned medium, DCs were
isolated by FACS sorting and 2.5-3 × 104 DCs were cultured
for 48 hours in 100 μL complete RPMI medium with 10 μM
L-tryptophan, indicated stimuli and with or without 10 μM
epacadostat. DCs from three different donors were pooled at
the same ratio for each subset to obtain a sufficient number
of cells and to even out donor variation. After 48 h, 75 μL of
this conditioned medium was added to 75 μL complete RPMI
medium containing 1.5 × 105 PBLs and 3 × 104 anti-CD3/CD28
beads (Gibco). After 3 days, proliferation was assessed by adding
1 μCi [0.037 MBq]/well of tritiated thymidine (MP Biomedicals,
Irvine, CA) to the cells. Tritium incorporation over 16 h was
measured with a scintillation counter. All experiments were
performed in triplicate for cDC2s and pDCs and in duplicate for
cDC1s.
For classical MLR assays, DCs were isolated by FACS sorting
and 2.5-4 × 104 DCs (always the same numbers across subsets)
were cultured for 16 h in 100 μL complete RMPI medium with
10 μM L-tryptophan, indicated stimuli and with or without
10 μM epacadostat. Then, 1.5 × 105 PBLs were added and
incubated with the DCs for 3 days. Proliferation was assessed by
tritiated thymidine incorporation as above. All experiments were
performed in triplicate for cDC2s and pDCs and in duplicate for
cDC1s.
Antigen cross-presentation assay
Jurkat T cells transduced with CD8 and the α and β chains of a
T cell receptor specific for the HLA-A2.1-restricted gp100(280-288)
peptide (JE6.1 fl296; described previously [51]) were cultured
in RPMI supplemented with 2 mM ultraglutamine, 1% antibiotic-
antimycotic and 10% fetal bovine serum (Greiner Bio-One,
Kremsmünster, Austria). Positivity for the gp100-specific TCR was
monitored by flow cytometry with anti-TCR-V-β14-PE (Immuno-
Tools).
DCs were isolated from buffy coats or apheresis products of
HLA-A2.1+ donors by FACS sorting and cultured at 1 × 104
DCs/well in complete RPMI with 1 μM L-tryptophan, indicated
stimuli and with or without 10 μM epacadostat. In addition, DCs
were loaded with 1 μM gp100(154-162), 1 μM gp100(280-288), or 50
μM gp100(272-300) peptide (all JPT peptide technologies, Berlin,
Germany). After 16 h of culture, 5 × 104 JE6.1 fl296 T cells
were added directly to the DCs and cultured for another 24 h.
The cells were labeled with anti-CD3-FITC (BD Biosciences), anti-
CD69-APC (eBioscience) and fixable viability dye eFluor-780 to
determine the percentage of CD69high cells among live CD3+ T
cells. All experiments were performed in singlicate for conditions
with cDC1s and in duplicate for conditions with cDC2s and pDCs.
Statistical analysis
Statistical analysis was performed using GraphPad Prism software
version 7 (GraphPad Software Inc, San Diego, CA). Details on the
performed statistical tests can be found in the figure legends. Sta-
tistical significance was defined as: ns, P > 0.05; *P < 0.05; **P <
0.01; ***P < 0.001.
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